LOGIN  |  REGISTER
Cue Biopharma

Varex Imaging Management to Participate in Upcoming Investor Conferences

February 02, 2025 | Last Trade: US$11.97 0.08 0.67

SALT LAKE CITY / Feb 02, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences.

  • BTIG at Snowbird: The 12th Annual MedTech, Digital Health, LS&D Tools Conference in Salt Lake City, UT – Wednesday, February 12, 2025 (1x1 meetings only)
  • B. Riley Securities Precision Oncology & Radiopharma Conference – Friday, February 28, 2025 in New York, NY (1x1 meetings only)

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page